嵌合抗原受体T细胞治疗在发生与未发生细胞因子释放综合征的患者中疗效相似
该多中心回顾性分析纳入美国8家学术医学中心352例接受阿基仑赛或替沙仑赛治疗的大B细胞淋巴瘤成人患者,262例(74.4%)发生细胞因子释放综合征(CRS)。发生与未发生CRS的患者在无进展生存(P=.99)、总生存(P=.16)、完全缓解率和总缓解率上均无显著差异。
要点
- 352例接受商业化抗CD19 CAR-T治疗的大B细胞淋巴瘤患者中,262例(74.4%)发生CRS。
- 发生与未发生CRS的患者无进展生存(P=.99)和总生存(P=.16)无显著差异。
- 发生与未发生CRS的患者完全缓解率和总缓解率无显著差异。
核心结论
- 在这项回顾性分析中,发生CRS的患者接受商业化抗CD19 CAR-T细胞治疗后的临床结局与未发生CRS的患者相似。
研究设计与样本
- 多中心回顾性分析,纳入美国8家学术医学中心352例接受阿基仑赛或替沙仑赛治疗的大B细胞淋巴瘤成人患者。
主要发现
- 352例患者中262例(74.4%)发生CRS。
- 发生与未发生CRS的患者无进展生存无显著差异(P=.99),总生存无显著差异(P=.16)。
- 发生与未发生CRS的患者完全缓解率和总缓解率无显著差异。
- 多因素分析中,治疗期间铁蛋白峰值>5000 ng/mL与无进展生存和总生存显著更差相关。
- 多因素分析中,淋巴细胞清除化疗前乳酸脱氢酶高于本机构正常上限与无进展生存和总生存显著更差相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of many patients with aggressive relapsed or refractory large B-cell lymphoma (LBCL). Treatment can be complicated by clinically evident cytokine release syndrome (CRS), which is characterized by the development of fever, hypoxia, and hypotension, and can be life-threatening. Most patients treated with CAR-T cells develop CRS, which is thought to represent an immune phenomenon. It was previously unknown whether patients who did not develop CRS had reduced CAR-T cell activity and were therefore likely to have worse outcomes. We conducted a multicenter retrospective analysis of 352 adult patients treated at 8 academic medical centers in the United States who received axicabtagene ciloleucel or tisagenlecleucel for the treatment of LBCL. The outcomes of interest included progression-free survival, overall survival, complete response rate, and overall response rate. Of the included patients, 262 (74.4%) developed CRS. There was no significant difference in progression-free survival (P = .99) or overall survival (P = .16) between patients who developed CRS and those who did not develop CRS. Peak ferritin levels >5000 ng/mL during treatment and lactate dehydrogenase levels greater than the institutional upper limit of normal before lymphodepleting chemotherapy were associated with significantly worse progression-free and overall survival in the multivariate analysis. There was no significant difference in the complete response or overall response rates between patients who did and did not develop CRS. In this retrospective analysis, we report that patients who develop CRS have clinical outcomes similar to those of patients without CRS treated with commercial anti-CD19 CAR-T cells.
引用
- Bhaskar ST, Patel VG, Porter DL, et al. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023. PMID: 36508286. doi:10.1182/bloodadvances.2022008937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。